Anti-Interleukin-5 Therapy in Severe Asthma

European Respiratory Review - United Kingdom
doi 10.1183/09059180.00004013
Full Text
Abstract

Available in full text

Date
Authors
Publisher

European Respiratory Society (ERS)

Related search

A Review of Three New Anti-Interleukin-5 Monoclonal Antibody Therapies for Severe Asthma

Cureus
2018English

Comparison of Anti-Interleukin-5 Therapies in Patients With Severe Asthma: Global and Indirect Meta-Analyses of Randomized Placebo-Controlled Trials

Clinical and Experimental Allergy
AllergyImmunology
2016English

Efficacy of Anti-Interleukin-5 Therapy With Mepolizumab in Patients With Asthma: A Meta-Analysis of Randomized Placebo-Controlled Trials

PLoS ONE
Multidisciplinary
2013English

The Potential Role of Interleukin-17 in Severe Asthma

Current Allergy and Asthma Reports
ImmunologyPulmonaryAllergyRespiratory Medicine
2011English

Biologic Therapy in Severe Asthma: An Update

Archives of Asthma, Allergy and Immunology
2019English

Eosinophils Target Therapy for Severe Asthma: Critical Points

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2018English

Reslizumab: Add-On Therapy for Severe Eosinophilic Asthma

Prescriber
Pharmacology
2017English

Anti-Inflammatory Mechanisms of the Novel Cytokine Interleukin-38 in Allergic Asthma

Cellular and Molecular Immunology
Infectious DiseasesMedicineAllergyImmunology
2019English

Pharmacoeconomic Analysis of Therapy With Reslizumab in Severe Eosinophilic Asthma

Pulmonologiya
PulmonaryRespiratory Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy